TY - JOUR T1 - Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal JO - PharmacoEconomics UR - http://eprints.whiterose.ac.uk/91088/ PY - 2016/03/01 AU - Essat M AU - Tappenden P AU - Ren S AU - Bessey A AU - Archer R AU - Wong R AU - Lobo A AU - Hoque S ED - DO - DOI: 10.1007/s40273-015-0334-3 PB - Springer Science and Business Media LLC VL - 34 IS - 3 SP - 245 EP - 257 Y2 - 2025/04/09 ER -